The Duchenne muscular dystrophy gene therapy developer has achieved the first close of a series C round backed by existing investor Biogen.

OrCam, a smart camera developer backed by Intel, is considering an initial public offering a month after raising a previously unannounced $41m funding round.

SpyBiotech has been spun out of University of Oxford with $5m in seed capital led by Oxford Sciences Innovation and participation from GV.

Optum Ventures added $7.5m to help life sciences data platform Shyft Analytics close a $20m series B round with backing from McKesson and Medidata.

Novartis is set to exit heart valve replacement maker Symetis after Boston Scientific agreed a cash purchase less than two weeks after the company filed to go public.

The medical access platform has secured $200m in a Tencent-led series D round that took followed a $60m round two years ago.

Osage University Partners was among the investors in the University of California San Diego spinout's latest round, which will support phase 1 trial for its lead compound.

Antiva Biosciences, which is developing therapies to treat lesions that cause cervical cancer, has raised $22m in a series C round led by the venture capital arm of EMS.

JD.com co-led the healthcare access app developer's series A round two years after acquiring a 10% stake in its listed parent company.